Release Date: November 13, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Could you elaborate on the potential for expanding C 155 into additional patient populations like auto HSCT and cancer neutropenia? Would these require separate phase one studies, or could they be part of a basket trial? Also, would you pursue these independently or with a partner? A: (Eric Schafft, CEO) The mechanism of C 155 is applicable to both allo and auto HSCT, among other populations. We are considering synergies in clinical trial design, potentially through a basket study. We don't anticipate needing to start over with phase one due to the established safety profile. We are open to partnerships to accelerate these efforts.
Q: Can you explain the differences between C 147 and C 155 in terms of composition and target pathogens? A: (Dr. Lisa Von Molke, Chief Medical Officer) C 155 and C 147 are different bacterial consortia. C 155 targets pathogens common in hematopoietic stem cell transplant patients, while C 147 is optimized for pathogens in chronic liver disease patients. Both aim to improve epithelial barrier integrity.
Q: What are you looking for in a potential partner for C 155, and what is your timeline for securing a partnership? A: (Eric Schafft, CEO) We seek partners who can provide capital and capabilities to accelerate C 155's development, especially for global studies. We aim for alignment in values and objectives. While we are actively pursuing partnerships, timelines can be unpredictable. We are preparing to move forward independently if necessary.
Q: How do you envision Seres Therapeutics' role in the biotech space over the next 3-5 years? Will you focus on being a research and discovery arm, or do you plan to commercialize products independently? A: (Eric Schafft, CEO) We aim to be an engine for creating multiple therapeutic opportunities, starting with C 155. Our long-term goal is to be vertically integrated, potentially commercializing products with a focused footprint. However, our current focus is on R&D and partnerships to drive shareholder value.
Q: What are the financial implications of the VTT sale, and how does it impact your cash runway and operational focus? A: (Marilla THL, CFO) The VTT sale provided a significant capital infusion, allowing us to retire debt and reduce our cash burn rate. We expect to fund operations into Q4 2025. The transaction enables us to focus on advancing our live biotherapeutic programs with a streamlined team.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.